Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.33 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798586 | 0.82 | MAPT (0.34) | MEN1KMT2AALDH1A1 | |
| SCHEMBL6793133 | 0.81 | KMT2A (0.40) | MEN1KMT2AALDH1A1 | |
| SCHEMBL6791584 | 0.81 | MEN1 (0.36) | MEN1KMT2AADORA3TGFBR1TGFBR2 | |
| SCHEMBL6792068 | 0.81 | MEN1 (0.36) | MEN1KMT2AADORA3TGFBR1TGFBR2 | |
| SCHEMBL6794842 | 0.79 | OPRD1 (0.35) | MEN1KMT2ACHRM2CHRM4CHRM5 | |
| SCHEMBL6795358 | 0.77 | ADORA3 (0.33) | ADORA3CHRM5CHRM1ALDH1A1 | |
| SCHEMBL6792562 | 0.71 | AURKA (0.51) | MEN1KMT2ACHRM2CHRM4CHRM5 | |
| SCHEMBL6793950 | 0.70 | CCNA2 (0.39) | ALDH1A1 | |
| SCHEMBL24103840 | 0.69 | KMT2A (0.45) | MEN1KMT2AADORA3ALDH1A1 | |
| SCHEMBL6798193 | 0.68 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | MEN1 1382/4885KMT2A 1257/4885ADORA3 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.